Shai Mulinari

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 14

Top Topics

Traumatic Brain Injury

Molecular Dynamics Simulations

Transcription Factor

Drug Administration

Top Venues

Sociology of health & illness

Clinical and translational science

Health research policy and systems

This page only lists publications with an associated author ORCID identifier.

Publications

Hayase Hakariya, Frank Moriarty, Akihhiko Ozaki, Shai Mulinari, Hiroaki Saito, Tetsuya Tanimoto
Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals. Clinical and translational science 17 (7) (2024)
Hayase Hakariya, Frank Moriarty, Akihhiko Ozaki, Shai Mulinari, Hiroaki Saito, Tetsuya Tanimoto
Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals. Clinical and translational science 17 (7) (2024)
Piotr Ozieranski, Eszter Saghy, Shai Mulinari
Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database. PloS one 18 (11) (2023)
Shai Mulinari, Anna Bredström
Race in clinical trials in Sweden: How regulatory and medical standards in clinical research trump the post-racial discourse. Sociology of health & illness (2023)
Piotr Ozieranski, Luc Martinon, Pierre-Alain Jachiet, Shai Mulinari
Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe. International journal of health policy and management (2022)
Anna Bredström, Shai Mulinari
Conceptual unclarity about COVID-19 ethnic disparities in Sweden: Implications for public health policy. Health (London, England : 1997) (2022)
Alice Fabbri, Shai Mulinari, Martin Johansson, Weda Ghaur, Abdullah Muhammad Khalil, Andreas Lundh
Content and strength of conflict of interest policies at Scandinavian medical schools: a cross sectional study. BMC medical education 22 (1) (2022)
Dylan Pashley, Piotr Ozieranski, Shai Mulinari
Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise? International journal of health services : planning, administration, evaluation 52 (3) (2022)
Piotr Ozieranski, János György Pitter, Emily Rickard, Shai Mulinari, Marcell Csanádi
A 'patient-industry complex'? Investigating the financial dependency of UK patient organisations on drug company funding. Sociology of health & illness (2021)
Shai Mulinari, Andreas Vilhelmsson, Emily Rickard, Piotr Ozieranski
Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs. PloS one 15 (6) (2020)
Shai Mulinari, Courtney Davis
The will of Congress? Permissive regulation and the strategic use of labeling for the anti-influenza drug Relenza. Social studies of science 50 (1) (2019)
Shai Mulinari, Andreas Vilhelmsson
Revisiting the pharmaceuticalisation of pandemic influenza using Lukes' framework of power. Sociology of health & illness 42 (2) (2019)
Shai Mulinari, Courtney Davis
Regulatory scientists' work has important ramifications for public health and should be open to public scrutiny. Health research policy and systems 16 (1) (2018)
Shai Mulinari, Courtney Davis
Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of 'deep' product reviews. Health research policy and systems 15 (1) (2017)